Pharmacokinetics and Safety of UI087 Compared to Coadministration of UIC202506, UIC202507 and UIC202508 in Healthy Volunteers

Phase 1, randomised, open-label trial of dapagliflozin + sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Korea United Pharm Inc. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration at 72 hours and Maximum Observed Plasma Concentration at 72 hours. Planned start Apr 2026; status: not yet recruiting.